HIV encephalopathy with bilateral lower limb spasticity: gross motor function and antiretroviral therapy

Developmental Medicine and Child Neurology

Volumn 59, Issue 4, 2017, Pages 407-411

  Mann, Theresa N ^a,b   Laughton, Barbara ^b   Donald, Kirsten A ^a   Langerak, Nelleke G ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

AGE; ANTIRETROVIRAL THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUNCTIONAL STATUS; GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM; GROSS MOTOR FUNCTION MEASURE; HIV ASSOCIATED DEMENTIA; HUMAN; JUMPING; LOWER LIMB; MALE; MOBILIZATION; MOTOR PERFORMANCE; PRIORITY JOURNAL; RUNNING; SCHOOL CHILD; SPASTICITY; STANDING; VIRUS LOAD; WALKING; AIDS DEMENTIA COMPLEX; COMPLICATION; DISABILITY; DRUG EFFECTS; MOTOR ACTIVITY; MUSCLE SPASTICITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

AIDS DEMENTIA COMPLEX; ANTI-RETROVIRAL AGENTS; CHILD; DISABILITY EVALUATION; FEMALE; HUMANS; LOWER EXTREMITY; MALE; MOTOR ACTIVITY; MUSCLE SPASTICITY; OUTCOME ASSESSMENT (HEALTH CARE); SEVERITY OF ILLNESS INDEX;

EID: 85014125913     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/dmcn.13377     Document Type: Article

References (22)

1. UNAIDS. Fact sheet 2016. 2016. Available at: http://www.unaids.org/en/resources/campaigns/HowAIDSchangedeverything/factsheet (accessed 23 November 2016).
2. Sei S, Stewart SK, Farley M, et al. Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. J Infect Dis 1996; 174: 1200–06.
3. McCoig C, Castrejón MM, Castaño E, et al. Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. J Pediatr 2002; 141: 36–44.
4. Mitchell CD. HIV-1 encephalopathy among perinatally infected children: Neuropathogenesis and response to highly active antiretroviral therapy. Ment Retard Dev Disabil Res Rev 2006; 12: 216–22.
5. Sánchez-Ramón S, Cantó-Nogués C, Muñoz-Fernández A. Reconstructing the course of HIV-1-associated progressive encephalopathy in children. Med Sci Monit 2002; 8: RA249–A252.
6. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43: 1–10.
7. Chiriboga CA, Fleishman S, Champion S, Gaye-Robinson L, Abrams EJ. Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART). J Pediatr 2005; 146: 402–07.
8. Cooper ER, Hanson C, Diaz C, et al. Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection. Women and Infants Transmission Study Group. J Pediatr 1998; 132: 808–12.
9. Sánchez-Ramón S, Resino S, Bellón Cano JM, Ramos JT, Gurbindo D, Muñoz-Fernández A. Neuroprotective effects of early antiretrovirals in vertical HIV infection. Pediatr Neurol 2003; 29: 218–21.
10. Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS 2009; 23: 1893–901.
11. UNAIDS AIDSinfo. Treatment, coverage of people receiving ART, children (0–14). 2015. Available at: http://aidsinfo.unaids.org/# (accessed 6 November 2015).
12. Donald KA, Walker KG, Kilborn T, et al. HIV Encephalopathy: pediatric case series description and insights from the clinic coalface. AIDS Res Ther 2015; 12: 1–10.
13. Hilburn N, Potterton J, Stewart A. Paediatric HIV encephalopathy in sub-Saharan Africa. Phys Ther Rev 2010; 15: 410–17.
14. Walker KG, Inglis M, Norton G, et al. Orphans, HIVE and HAND: who are the watch-keepers? South African Med J 2014; 104: 678.
15. Langerak NG, du Toit J, Burger M, Cotton MF, Springer PE, Laughton B. Spastic diplegia in children with HIV encephalopathy: first description of gait and physical status. Dev Med Child Neurol 2014; 56: 686–94.
16. Micklesfield LK, Levitt NS, Carstens MT, Dhansay MA, Norris SA, Lambert EV. Early life and current determinants of bone in South African children of mixed ancestral origin. Ann Hum Biol 2007; 34: 647–55.
17. Rosenbaum PL, Palisano RJ, Bartlett DJ, Galuppi BE, Russell DJ. Development of the Gross Motor Function Classification System for cerebral palsy. Dev Med Child Neurol 2008; 50: 249–53.
18. Palisano RJ, Rosenbaum P, Bartlett D, Livingston MH. Content validity of the expanded and revised Gross Motor Function Classification System. Dev Med Child Neurol 2008; 50: 744–50.
19. Bjornson KF, Graubert CS, Buford VL, McLaughlin J. Validity of the Gross Motor Function Measure. Pediatr Phys Ther 1998; 10: 43–47.
20. Bjornson K, Graubert C, McLaughlin J. Test-retest reliability of the Gross Motor Function Measure in children with cerebral palsy. Pediatr Phys Ther 2000; 12: 200–02.
21. Ross SA, Engsberg JR. Relationships between spasticity, strength, gait, and the GMFM-66 in persons with spastic diplegia cerebral palsy. Arch Phys Med Rehabil 2007; 88: 1114–20.
22. Innes S, Lazarus E, Otwombe K, et al. Early severe HIV disease precedes early antiretroviral therapy in infants: are we too late? J Int AIDS Soc 2014; 17: 1–6.